Related Experiment Video
Updated: Aug 18, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Management of phenylketonuria and hyperphenylalaninemia: the French guidelines]
V Abadie1, J Berthelot, F Feillet
1Fédération de pédiatrie, hôpital Necker-Enfants-Malades, assistance publique-hôpitaux de Paris, 149, rue de Sèvres, 75015 Paris, France. veronique.abadie@nck.ap-hop-paris.fr
Insights
Phenylketonuria (PKU), an inherited metabolic disorder, requires early low-phenylalanine diet intervention. Lifelong monitoring is crucial for managing PKU and preventing maternal PKU complications.
Area of Science:
- Metabolic disorders
- Genetics
- Public health
Context:
- Phenylketonuria (PKU) affects 1 in 15,000 births.
- France implemented national neonatal screening for PKU in 1978.
- Established national guidelines ensure optimal patient diagnosis and treatment.
Purpose:
- To outline the established French guidelines for PKU diagnosis and management.
- To detail the dietary interventions and monitoring protocols for PKU patients.
- To emphasize the importance of lifelong follow-up for PKU management and maternal PKU prevention.
Summary:
- PKU management involves a low-phenylalanine diet initiated in the neonatal period.
- Plasma phenylalanine levels should be maintained between 2-5 mg/dl until age 10.
- Dietary relaxation is permitted post-adolescence with continued monitoring, and lifelong follow-up is essential.
Impact:
- Early and consistent PKU management improves patient outcomes.
- Adherence to guidelines ensures standardized care across regional centers.
- Lifelong monitoring prevents complications associated with PKU and maternal PKU.
Abstract:
Phenylketonuria (PKU) is an inherited metabolic disease affecting about one birth out of 15 000. From 1978, a national systematic neonatal screening was set up in France with a regional organisation. French rational and guidelines have been established by the national PKU group with the collaboration of all the physicians responsible for the regional centres. These guidelines specify the minimal diagnosis procedures leading to an optimal treatment of all patients. A low-phenylalanine diet must be started as soon as possible in the neonatal period for all newborns whose phenylalanine levels are above 10 mg/dl. The dietary control must keep the phenylalanine plasma levels between 2 and 5 mg/dl until 10 years of age. After this age, several data argue for a progressive and controlled relaxation of the diet, keeping the phenylalanine level below 15 mg/dl until the end of the adolescence and below 20 to 25 mg/dl in adulthood. All PKU patients must be followed up for life, in order to screen those who may not bear the diet relaxation and in order to strictly prevent maternal PKU deleterious consequences.
More Related Videos
Related Concept Videos
Inborn Errors of Metabolism
Chronic Kidney Disease III: Interprofessional Care
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

